Dephosphorylated uncarboxylated Matrix-Gla-Protein as candidate biomarker for immune-mediated vascular remodeling and prognosis in pulmonary hypertension Authors: R Tobal, J Potjewijd, F de Vries, D PC van Doorn, A Jaminon, R Bittner, C Akbulut, V van Empel, P Heeringa, J Damoiseaux, L Schurgers, P van Paassen Published: 2024 ABSTRACT AbstractPulmonary arterial hypertension (PAH) is a disease characterized by pulmonary vascular remodeling. Since dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP) is associated with cardiovascular mortality in systemic sclerosis, a disease associated with PAH, and immune-system involvement in PAH is increasingly recognized, we investigated the relationship between dp-ucMGP, vascular remodeling and soluble immune-checkpoint proteins in PAH. This prospective cohort study included patients with idiopathic (I)PAH, connective tissue disease (CTD)-PAH, chronic thrombo-embolic PH (CTEPH) and CTD patients without PAH. Patients with IPAH and CTD-PAH were stratified by clinical signs of immune-mediated inflammatory disease (IMID). We measured dp-ucMGP plasma levels, soluble immune-checkpoint proteins (sICPs), and vascular smooth muscle cell (iVSMC) calcification. We found elevated dp-ucMGP levels in all PAH subtypes and CTD patients compared to healthy controls. PAH patients showed increased iVSMC calcification, but no direct correlation was found with dp-ucMGP. IMID-PAH patients had higher dp-ucMGP levels than non-IMID PAH patients. dp-ucMGP correlated with several sICPs in both IPAH and CTD patients; multiple sICPs were elevated in IMID PAH patients. High dp-ucMGP levels in IPAH patients were associated with worse survival. Our findings suggest dp-ucMGP as a potential biomarker of immune-mediated vascular remodeling in PAH. Hence, dp-ucMGP, could help identify PAH patients who might benefit from immunosuppressive therapies.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-024-77000-w.Keywords: Pulmonary hypertension, Vascular remodeling, Dp-ucMGP, Inflammation, Immune checkpoint proteins, BiomarkersSubject terms: Biochemistry, Immunology, Biomarkers, Translational research Introduction Pulmonary arterial hypertension (PAH) is a complex and debilitating condition characterized by elevated blood pressure within the pulmonary arteries, leading to increased strain on the right side of the heart1. This chronic condition has a great impact on patient well-being and life expectancy2,3. The increase in pulmonary arterial pressure parallels structural changes in the pulmonary vasculature, which is characterized by increased muscularization, fibrosis, and gradual narrowing of blood vessels4. This pulmonary vascular remodeling involves the complex and incompletely understood interaction of endothelial cells (ECs), vascular smooth muscle cells (VSMCs) and fibroblasts4. The immune system is an important driver of this interaction, which is best illustrated by the elevated risk of developing PAH in patients with systemic autoimmune diseases such as systemic sclerosis (SSc) and systemic lupus erythematosus (SLE)5. Interestingly, even in idiopathic PAH (IPAH) there is ample evidence for immune activation and dysregulation during the disease course6–8. T -and B-cell infiltrates have been found around prototypical pulmonary vascular lesions in PAH patients and in both preclinical models and in numerous patients, autoantibodies such as anti-endothelial cell antibodies, immune complexes, or increased cytokine levels have been observed8–12. IgG from a subset of IPAH patients induces increased vascular cellular adhesion molecule-1 (VCAM-1), integrin cellular adhesion molecule-1 (ICAM-1), monocyte chemo-attractant protein-1 MCP-1 and interleukin-6 (IL-6) production in cultured endothelial cells13. However, the diagnostic and therapeutic approach with focus on the role of the immune system in the clinical practice of PAH patients is ill-defined and non-standardized. The strongest benefit from immunosuppression is shown in SLE-PAH, whereas this treatment is less or not effective in limited SSc-PAH14. This may indicate differences in pathogenesis and disease progression but also highlights the diagnostic delay in many PAH patients. Therefore, novel biomarkers are necessary to improve a more detailed understanding of the role and stage of immune activation related to the process of pulmonary vascular remodeling leading to PAH. We hypothesize that dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP) could be such a novel marker. We recently showed that plasma levels were increased in early systemic sclerosis patients, as compared to age-matched healthy controls15,16. Notably, dp-ucMGP levels exhibited a positive correlation with disease severity and the incidence of cardiovascular events in these patients. These findings were not explained by traditional cardiovascular risk factors. MGP is mostly known as a protein (14 kD) predominantly secreted by VSMCs and ECs, which plays a pivotal role as a vitamin K-dependent protein in inhibiting both intimal and medial vascular calcification. dp-ucMGP represents the fully inactive form, lacking the ability to bind calcium or extracellular matrix, and is consequently released into the circulation. SSc patients have a high risk of developing PAH over time, so we questioned whether dp-ucMGP may provide a link between inflammation and vasculopathy in PAH. Such a connection has also been suggested between the increased signaling pathways of TGF- β and bone morphogenetic protein 4 (BMP-4) that is observed in both systemic sclerosis and PAH17–21. In the present study we first measure plasma dp-ucMGP in patients with idiopathic PAH (IPAH), connective tissue disease-associated PAH (CTD-PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and in patients suffering from connective tissue disease (CTD) alone. We subsequently classify all patients as either immune-mediated inflammatory PAH (IMID-PAH) or non-IMID PAH according to the strict but non-validated criteria we use in our clinical practice. In addition, we measure soluble immune checkpoint proteins (sICPs), once thought to be solely cell membrane-bound regulators of immune cell function, but now recognized as biologically active molecules similar to stimulatory or inhibitory cytokines22,23. Unlike cytokines or chemokines, sICPs may reflect subtle chronic low-grade inflammatory processes, such as T-cell exhaustion and immune senescence, which have been observed in IPAH24. aim to explore whether sICPs are a valuable tool for detecting immune profiles within PAH and whether these profiles support the concept of IMID-PAH. Lastly, we investigated functional induced vascular smooth muscle cell (iVSMC) calcification as a readout of vascular damage in these patients. This assay, in which fluorescently labled fetuin-A, Ca2+ and patient plasma is added to iVSMCs, may indicate various pathophysiological mechanisms, such as altered VSMC signaling pathways, increased oxidative stress, or switching of VSMCs into a pro-inflammatory or synthetic phenotype.Altogether, we hypothesize that plasma dp-ucMGP may serve as a valuable biomarker for both immune-mediated disease severity and survival prognosis in PAH. Methods Study design and participants This study cohort consists of participants from the volatile organic compound-PAH (VOC-PAH) study, an observational prospective cohort study in IPAH, CTD-PAH, CTEPH, and CTD patients conducted between 2018 and 2023 at the Maastricht University Medical Center, Center of Expertise for PAH, in the Netherlands. Normative controls were obtained from the PREVEND-study25. The study was performed in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice, and ethical approval was obtained from the Medical Research Ethics Committee of Maastricht University Medical Center (MUMC+). Written informed consent was obtained from each participant. This study is registered with clinicaltrials.gov number NCT03819777. Adults with IPAH, CTD-PAH, CTEPH, or CTD classified according to current criteria were included. The exclusion criteria were not being treatment naïve, age < 18 years, or incapable of understanding or signing informed consent. All patients were analyzed for the presence of underlying immune activity or auto-immunity by performing a comprehensive immunological assessment. Next, all PAH patients were subcategorized as either immune-mediated inflammatory disease (IMID)-PAH or non-IMID PAH. This approach is supported by emerging evidence suggesting that immune dysregulation may play a role in the pathogenesis of IPAH6,7,9,10,26. Predefined IMID was defined by the presence of either auto-antibodies, including IgM rheumatoid factor or cryoglobulins, as sign of B-cell activity, and/or increased sIL-2R, as sign of T-cell activity. C-reactive protein was measured as indicator of inflammation, and the presence of (sub)acute infection was ruled out in all patients. All these parameters were assessed around the time of diagnosis, that is right heart catheterization. CTD patients without PAH were used as a disease control cohort. The disease duration of the CTD patients was defined as the time from the first non-Raynaud phenomenon manifestation; the IPAH patients were included within one month of diagnosis by right heart catheterization. Oral corticosteroids and hydroxychloroquine were permitted if the patient was on a stable dose regimen for more than three months prior to the baseline visit. No other background immunomodulatory therapies were allowed. Demographic data, as well as data on inflammatory parameters in the blood (C-reactive protein (CRP), soluble interleukin-2 receptor (sIL-2R)), pulmonary function tests (percentage of predicted forced vital capacity (%pFVC), and percentage of predicted diffusing capacity for carbon monoxide (%pDLCO)), 6-minutes walking test (6-MWT), New-York Heart Association (NYHA) class, echocardiography and if appropriate, right-sided heart catheterization, were recorded. Collection and processing of samples Blood samples were collectedat baseline, after obtaining informed consent of the participant, in ethylenediaminetetraacetic acid (EDTA) vials and centrifuged at 1300 g and room temperature for 10 min. The supernatant was carefully obtained and subsequently stored at -80oC. Measurement of plasma dp-ucMGP Circulating dp-ucMGP levels were determined in EDTA plasma in a single run by the Laboratory of Coagulation Profile (Maastricht, the Netherlands) using the commercially available IVD CE marked chemiluminescent InaKtif MGP assay on the IDS-iSYS system (IDS, Boldon, UK)27,28. Patient samples were incubated with magnetic particles coated with murine monoclonal antibodies against dpMGP, acridinium-labeled murine monoclonal antibodies against ucMGP, and assay buffer. The magnetic particles were captured using a magnet and washed to remove any unbound analyte. Trigger reagents were added, and the resulting light emitted by the acridinium label was directly proportional to the concentration of dp-ucMGP in the sample. This assay’s within-run and total precision were 0.8–6.2% and 3.0–8.2%, respectively. The assay measuring range was between 300 and 12,000 pmol/L and was found to be linear up to 11,651 pmol/L. Vascular smooth muscle cell calcification assay Calcification experiments were conducted with induced pluripotent stem cell (iPSC)-derived iVSMCs. iVSMCs were seeded in culture well plates at 1.0 × 104 cells/well. After 24 h, iVSMCs were cultured in calcification medium (DMEM, high glucose, GlutaMAX(TM), pyruvate (Thermo Fisher Scientific, catalog #31966), 5% IPAH, CTD-PAH, CTEPH or CTD patient plasma, 1% penicillin-streptomycin solution, and 3.6 mM Ca2+) for up to 9 days. Plasma samples were supplemented with 14.3 nM Hirudin to prevent coagulation upon re-calcifying the plasma. 5% healthy control pooled plasma was used as a negative control due to the lower magnitude of calcification. For the BioHybrid assay, Fetuin-A AlexaFluor-546 (1 µg/mL; prepared in-house) and Hoechst 33,342 (0.5 µg/mL, Invitrogen, Waltham, MA, USA) were supplemented at the start of the experiment29,30. At various time points after calcification induction, fluorescent images were taken in the RFP and DAPI channel (for cell count) were imaged for up to 9 days. Imaging was done with the Cytation 3 system (BioSPX, Abcoude, the Netherlands) and analyzed using Gen5 software v.3.10. (BioTek, Abcoude, the Netherlands). As readout, fluorescent RFP area/well was normalized against cell count. Measurement of soluble immune checkpoints The plasma concentrations of the sICPs were quantified using a commercially available multiplex immunoassay (Life Technologies; ProcartaPL HU-IMM96T: EPX140-15803-901), which measures the soluble concentrations of B- and T-lymphocyte attenuator (BTLA), glucocorticoid-induced TNFR-related protein (GITR), herpesvirus entry mediator (HVEM), indoleamine 2,3-dioxygenase (IDO), Lymphocyte-activation gene 3 (LAG3), programmed death protein-1 (PD1), programmed death ligand-1 (PDL1), programmed death ligand-2 (PDL2), T-cell immunoglobulin and mucin-domain containing-3 (TIM3), cluster of differentiation (CD)27, CD28, CD80, CD137 and CD152 (CTLA4/cytotoxic T-lymphocyte-associated antigen 4). The manufacturer’s protocols were followed by running patient samples in duplicates with 25 µL of plasma each and were measured using Magpix (Darmstadt, Germany). Data were analyzed using the xPONENT 4.2 software (Luminex). The given values represent the mean of the duplicates given in pg/mL. For checkpoint PDL1, many values were found to fall below the standard curve, and these results were excluded. Statistical analysis Data were analyzed using R and RStudio version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria), SPSS version 24.0 (IBM Corp., Armonk, NY), and GraphPad Prism version 9.5.0 (GraphPad Software, Boston, MA). Normally distributed variables were presented as mean ± standard deviation (SD). Skewed variables were presented as medians (interquartile range). The independent t-test, Mann-Whitney U-test, and Chi square/Fisher’s exact test were used as appropriate. A one-way analysis of variance or Kruskal-Wallis H-test was used when > 2 groups were compared. Pairwise correlation matrices were computed using Spearman’s rank correlation coefficient. Kaplan-Meier curves were compared using the log-rank test. P < 0.05 was considered statistically significant. Results Clinical characteristics of the study cohort Thirty-four PAH patients, 11 CTEPH patients and 28 CTD disease controls without PH were included from the prospective VOC-PAH cohort for dp-ucMGP and calcification analysis at baseline. PAH patients were first classified in IPAH (n = 26) and CTD-PAH (n = 8). The clinical characteristics at the time of presentation have been depicted in Table 1. Clinical characteristics of PAH patients with IMID and without IMID have been depicted in Supplemental Table 1. Sex, age and body mass index (BMI) did not differ significantly between the groups. Hemodynamic parameters did not differ significantly among PAH groups. Patients with IPAH were most likely to have heart failure class III or IV (n/N = 16/26, 62%), according to the New York Heart Association. Patients with CTEPH had the lowest forced expiratory volume after one second (FEV1), with a median percentage of 66%. Other pulmonary function parameters did not differ significantly among groups. None of the patients in this cohort were treated with immunosuppressive agents, including prednisolone or hydroxychloroquine, at time of sampling. The CTD disease control group mostly consisted of patients diagnosed with SSc (n/N = 27/28, 96%). sIL-2R concentrations were the highest in patients with CTD-PAH, with a median of 910 U/mL. CRP concentrations, however, did not differ significantly among groups. Table 1Baseline demographic and patient characteristics. Count (percentage), mean ± standard deviation, or median (interquartile range) were given, as appropriate.P-values were calculated using Chi-square / Fisher’s exact test, analysis of variance, or Kruskal-Wallis test, respectively. BMI, body mass index; NYHA, New-York Heart Association; 6MWT, six-minute walking test; NT-pro BNP, N-terminal pro brain natriuretic peptide; CRP, C-reactive protein; dp-ucMGP, dephosphorylated-uncarboxylated Matrix Gla-Protein; sIL-2R, soluble interleukin-2 receptor; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; FEV1%, forced expiratory volume %; FVC%, forced vital capacity %; TLC%, total lung capacity %; DLCO, carbon mono-oxide transfer coefficient; MCTD, mixed connective tissue disease; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; SS, Sjögren syndrome; RA, rheumatoid arthritis. One patient was diagnosed with RA and concomitant SS. P-values depicted with * were calculated based on comparison between IPAH, CTD-PAH and CTEPH patients. Baseline demographic and patient characteristics. Count (percentage), mean ± standard deviation, or median (interquartile range) were given, as appropriate. P-values were calculated using Chi-square / Fisher’s exact test, analysis of variance, or Kruskal-Wallis test, respectively. BMI, body mass index; NYHA, New-York Heart Association; 6MWT, six-minute walking test; NT-pro BNP, N-terminal pro brain natriuretic peptide; CRP, C-reactive protein; dp-ucMGP, dephosphorylated-uncarboxylated Matrix Gla-Protein; sIL-2R, soluble interleukin-2 receptor; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; FEV1%, forced expiratory volume %; FVC%, forced vital capacity %; TLC%, total lung capacity %; DLCO, carbon mono-oxide transfer coefficient; MCTD, mixed connective tissue disease; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; SS, Sjögren syndrome; RA, rheumatoid arthritis. One patient was diagnosed with RA and concomitant SS. P-values depicted with * were calculated based on comparison between IPAH, CTD-PAH and CTEPH patients. dp-ucMGP plasma levels in treatment-naïve IPAH, CTD-PAH, and CTEPH patients at diagnosis Plasma dp-ucMGP levels of 26 IPAH, 8 CTD-PAH and 11 CTEPH patients were compared with a control cohort of 28 age-matched CTD patients. Median dp-ucMGP levels were 795 (525.3;1027.0), 1029 (646.3;1336.0), 847 (593.0;1090.0), and 542 (374.3;757.8) pmol/L, respectively (Fig. 1). This is all greatly increased as compared to a median dp-ucMGP level of 375 (285.0;469.0) pmol/L in 400 age-matched Dutch HCs (p < 0.001). CTD-PAH patients had significantly higher dp-ucMGP levels than our control CTD patients (p = 0.017) (Fig. 1A). Subsequently, we stratified IPAH and CTD-PAH patients based on clinical signs of immune-mediated inflammatory disease (IMID). dp-ucMGP plasma levels had a median of 646 (519.8;758.3) in the non-IMID group and 911 (619.0;l166.0) in the IMID group which was significantly different (p = 0.030) (Fig. 1B). Plasma levels of dp-ucMGP in IPAH, CTD-PAH, CTEPH, and CTD patients. (A) Plasma levels of dp-ucMGP in IPAH (n = 26), CTD-PAH (n = 8), CTEPH (n = 11) and CTD (n = 28) patients. (B) Plasma levels of dp-ucMGP in non-IMID-PAH (n = 8) and IMID-PAH (n = 26) patients. Data are shown as symbols for individual patients or HCs. Patients depicted as red dots are categorized as CTD-PAH (n = 8), black dots depict IPAH patients (n = 18). The horizontal dotted line represents the mean value of dp-ucMGP in aged-matched healthy controls (393pmol/L). Horizontal gray bars represent median values with interquartile range. Statistical analysis was performed using the Kruskal-Wallis and Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. dp-ucMGP, dephosphorylated-uncarboxylated Matrix-GLA-Protein; IPAH, idiopathic pulmonary hypertension; CTD-PAH, connective tissue associated pulmonary arterial hypertension; CTEPH, chronic thrombo-embolic pulmonary hypertension; CTD, connective tissue disease; IMID, immune mediated inflammatory disease. Plasma of PAH and CTD patients can induce calcification of vascular smooth muscle cells (iVSMCs) in vitro To investigate the calcification potential of the same patients, plasma-induced calcification of iVSMCs was analyzed in the Biohybrid assay. Median calcification levels were 7.8 (4.2;12.2) in IPAH, 7.5 (3.5;16.4) in CTD-PAH, 6.4 (4.5;12.0) in CTEPH, and 6.8 (4.9;11.3) RPF µcm2/cell count in CTD patients, which were significantly increased compared to a median of 1.9 (0.07;3.2) in aged matched healthy controls (Fig. 2A). When IPAH and CTD-PAH patients were stratified based on IMID, no significant difference was observed with a median of 7.8 (10.4;3.9) in non-IMID PAH and 7.5 (4.;12.6) µcm2/cell in IMID-PAH patients (Fig. 2B). No statistical correlation was found between dp-ucMGP plasma levels and the amount of calcification (Fig. 4). Amount of plasma-induced calcification of induced vascular smooth muscle cells. (A) Plasma-induced iVSMC calcification in IPAH (n = 26), CTD-PAH (n = 8), CTEPH (n = 11), and CTD (n = 28) patients. (B) plasma-induced iVSMC calcification in IPAH non-IMID-PAH (n = 8) and IMID-PAH (n = 26) patients. Data are shown as symbols for individual patients or HCs. Horizontal bars represent median values with interquartile range. Patients depicted as red dots are categorized as CTD-PAH (n = 8), black dots depict IPAH patients (n = 18). Statistical analysis was performed using the Kruskal-Wallis and Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. RFP, red fluorescent protein; HC, healthy controls; IPAH, idiopathic pulmonary hypertension; CTD-PAH, connective tissue associated pulmonary arterial hypertension; CTEPH, chronic thrombo-embolic pulmonary hypertension; CTD, connective tissue disease; IMID, immune-mediated inflammatory disease. Correlation matrices for different soluble immune checkpoint proteins (sICPs) with dp-ucMGP and calcification in IPAH (n = 24) and CTD (n = 27) patients. Correlation coefficient was calculated using nonparametric Spearman pairwise correlation. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Soluble immune checkpoint protein levels and correlation with dp-ucMGP In IPAH and CTD patients, levels of sCD137 (p < 0.0001; p < 0.001), sCD152 (p < 0.001; p < 0.01), sBTLA (p < 0.001; p < 0.01), sLAG3 (p < 0.0001; p < 0.01), and sTIM3 (p < 0.0001; p < 0.05) were significantly elevated compared to healthy controls (Fig. 3). Additionally, sPD-L2 was significantly elevated in CTD patients compared to healthy controls (p < 0.001). No significant differences were observed between sICP levels in IPAH and CTD patients. dp-ucMGP plasma levels were correlated in IPAH patients with sBTLA, sCD137, sCD152, sCD27, sCD28, sGITR, sHVEM, and sIDO with a mean Spearman r of 0.56 (Fig. 4A). In CTD patients, dp-ucMGP plasma levels were correlated with all soluble ICs with a mean Spearman r of 0.52 (Fig. 4B). When PAH patients were subsequently stratified into non-IMID-PAH (n = 8) and IMID-PAH (n = 19) subgroups, as mentioned in the method section, several soluble checkpoint proteins were significantly elevated in the IMID group (Fig. 5). IMID-PAH patients exhibited higher levels of sCD28, sGITR, sPD-L2, sHVEM, sIDO and sLAG3 (p < 0.05), sCD137 and sBTLA (p < 0.01) and sPD-1 (p < 0.001). No significant differences were observed in sCD27, sCD80, sCD152, or sTIM3 between these groups. Plasma levels of different soluble immune checkpoint proteins (sICPs) in IPAH, CTD patients and healthy controls. The indicated sICPs were measured in plasma samples of 24 IPAH patients and 27 CTD patients. sICPs are classified as either co-stimulatory or co-inhibitory and are found on either T-cells or antigen-presenting cells. Horizontal bars represent median values with interquartile range. Statistical analysis was performed using the Kruskal-Wallis test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. sPD1, programmed death protein-1; sPDL2, programmed death ligand-2; sBTLA, soluble B- and T-lymphocyte attenuator; cluster of differentiation (CD)27, CD28, CD80, CD137 and CD152 (CTLA4/cytotoxic T-lymphocyte-associated antigen-3; sGITR, glucocorticoid-induced TNFR-related protein; sHVEM herpesvirus entry mediator; sIDO, indoleamine 2,3-dioxygenase; sLAG3, Lymphocyte-activation gene 3; sTIM3, T-cell immunoglobulin and mucin-domain containing-3. Plasma levels of different soluble immune checkpoint proteins (sICPs) in non-IMID-PAH and IMID-PAH patients. The indicated sICPs were measured in plasma samples of non-IMID-PAH (n = 8) patients and IMID-PAH (n = 19) patients. Horizontal bars represent median values with interquartile range. Statistical analysis was performed using the Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. dp-ucMGP as a new biomarker for prognosis of survival in IPAH patients We aimed to explore whether dp-ucMGP levels correlate with survival in IPAH, CTD-PAH and CTEPH. Groups were stratified based on high or low dp-ucMGP plasma levels accordingly. Cut-off values were estimated based on the 50th percentile, which was 795 in IPAH, 1029 in CTD-PAH and 847 pmol/L in CTEPH respectively. In IPAH (n = 26) 1, 3 and 5 year survival was 100% in the low dp-ucMGP group, compared to 51.3%, and both 42.7% in the high dp-ucMGP group. The difference in survival based on dp-ucMGP stratification was statistically significant (p = 0.003) (Fig. 6). Median survival time for the high dp-ucMGP group was 1.42 years. Survival was higher than 50% in the low dp-ucMGP group and median survival time was therefore undefined. Both CTD-PAH (n = 8) and CTEPH (n = 11) did not show a significant difference in survival when stratified based on high or low dp-ucMGP levels (Suppl. Figure 1). When survival was analyzed based on high or low sICPs in IPAH patients, only sCD137 showed a significant difference in survival (p = 0.003) (Suppl. Figure 2). Confounding factors were analyzed and showed a significant difference in DLCO and sIL-2R levels between high and low dp-ucMGP patients (Suppl. Figure 3). Kaplan-Meyer survival analyses for dp-ucMGP high/low of IPAH patients (n = 26). High/low cut-off values were based on the 50th percentile of dp-ucMGP plasma levels. Statistical analysis was performed using the log-rank test. Discussion In this single-center prospective cohort study we found significantly increased dp-ucMGP plasma levels in all PH subtypes (IPAH, CTD-PAH, CTEPH) and CTD patients compared to age-matched healthy controls. All PH patients demonstrated significantly higher iVSMC calcification compared to age-matched controls, suggesting that iVSMC in the presence of PH sera, and not healthy controls, adapts to a more proinflammatory and remodeling phenotype. Furthermore, while plasma dp-ucMGP levels of IPAH patients did not differ from CTD-PAH patients, IMID-PAH patients had significantly higher levels than non-IMID-PAH patients. IMID-PAH patients also exhibited higher levels of sPD-1, sPD-L2, sBTLA, sCD137, sGITR, sHVEM, sIDO, and sLAG3 compared to non-IMID PAH patientsdp-ucMGP levels correlated with several sICPs (sBTLA, sCD137, sCD152, sCD27, sCD28, sGITR, sHVEM, and sIDO) but not with iVSMC calcification. Interestingly, our analysis revealed that high baseline dp-ucMGP levels were associated with significantly worse survival in IPAH patients. While no confounding factors were immediately apparent, these patients did exhibit higher sIL-2R levels and lower DLCO. In recent years, dp-ucMGP emerged as a biomarker of vascular vitamin K status. Epidemiological data has highlighted an inverse association between dp-ucMGP levels and vitamin K status31,32. Earlier investigations involving patients with diabetic kidney disease and systemic sclerosis (SSc) have also documented elevated plasma levels of dp-ucMGP33,34. This plasma concentration is notably associated with heightened risks of cardiovascular mortality and vascular calcification as has been shown in hemodialysis patients as well as individuals with diabetes and heart failure35. However, the reason for the elevated dp-ucMGP levels has remained unclear. MGP is mostly studied for its protective role in vascular calcification. Vascular calcification triggers increased MGP transcription and, upon exhaustion of vitamin K, produces the inactive dp-ucMGP, which is released into the systemic circulation36. MGP contains five γ-carboxyglutamate amino-acid residues requiring post-translational carboxylation to be activated37. In addition to carboxylation, phosphorylation of the serine residues is important for the role of MGP in inhibiting vascular calcification37. MGP can bind directly to calcium-crystals thereby inhibiting further crystal growth38. Interestingly, there are similarities between the underlying mechanisms causing vascular calcification and the pathophysiological mechanisms involved in the development of PAH. MGP also binds to BMP-2 and 4 inhibiting their binding to the BMPR238. Recently, the research group led by Ten Dijke proposed a mechanism wherein pro-inflammatory cytokines IL-1b and TNF induce endothelial-to-mesenchymal transition (endoMT), sensitizing newly formed VSMCs to BMP-939. This induction promotes vascular calcification, with downregulation of the BMPR2 receptor identified as a crucial event in this process. Given that these pathophysiological mechanisms coincide with the dysfunctional pathways observed in PAH, particularly the downregulation of BMPR2, which is currently recognized as an effective therapeutic target influenced through Sotatercept, a potential common mechanism is conceivable17,18,21,40. However, vascular calcification has not yet been demonstrated in the context of PAH and is currently not acknowledged as a prominent histopathological characteristic41. This indicates that BMPR2 may be involved through a different mechanism. In PAH, features such as intimal fibrosis, arterial muscularization, and progressive VSMC proliferation are more evident4,42.Since we were unable to perform a comprehensive analysis of BMPR2 signaling pathways or genetic mutation screening, future studies should investigate the association between (dp-uc)MGP and BMPR2, especially considering its current potential therapeutic implications through Sotatercept in PAH. Despite the pathophysiological connection between calcification and MGP, this correlation does not seem to extend to the inactive form43. While we also did not find a direct correlation between dp-ucMGP levels and calcification in this study, all PAH and CTD patients demonstrated increased calcification propensity of iVSMCs in the Biohybrid assay. In this assay patient plasma, fluorescently labeled fetuin-A and Ca2+ is added to iVSMCs. Although as compared to controls we claim to have demonstrated the changes in VSMCs, this does not necessarily imply increased calcification in vivo, such as in atherosclerosis, in our PAH patients. This finding, rather than solely indicating increased calcification propensity of VSMCs, also suggests a shift toward a more synthetic VSMC phenotype44. Such a phenotypic change is associated with inflammation and the extensive vascular remodeling observed in both PAH and CTD4,45. Elevated levels of dp-ucMGP could indicate a compensatory response to vascular stress or damage, aiming to prevent calcification rather than serving as a direct marker of existing calcification. As many of these mechanisms are multifaceted, certain features may instigate VSMC calcification or processes more commonly observed in PAH, such as VSMC proliferation or, potentially, VSMC senescence or inflammatory phenotype transition4,45. Increased dp-ucMGP levels in this cohort of patients with extensive pulmonary or systemic vascular remodeling have led to questions by which mechanisms these levels are increased. The precise triggers of increased dp-ucMGP plasma levels in our patients, as well as the primary cell types responsible, remain to be elucidated. It is necessary to determine whether there is inhibition in the conversion to active MGP, increased mechanisms that could lead to MGP deactivation, the potential impact of endoplasmic reticulum stress, and the contribution of inflammatory processes in these mechanisms. Additional in-vitro experiments, also focusing on VSMC proliferation, migration and endothelial-VSMC interactions, particularly utilizing material from PAH patients, should be directed toward elucidating these mechanisms. Considering prior evidence indicating that a subset of IPAH patients may display greater immunological involvement than others, the importance of a biomarker capable of distinguishing these patients has greatly increased7,11–13,46. This is particularly important as current therapeutic strategies for both IPAH and mostly CTD-PAH patients, with the exception for SLE-PAH, do not involve immunosuppressive treatment14. Instead, the focus currently remains on vasodilative therapy, which is not curative1. In this study, we have shown a strong connection between increased dp-ucMGP levels and inflammation. Both PAH and CTD patients with higher sICP levels and/or clinical signs of an immune-mediated disease have shown increased levels of dp-ucMGP. Besides, plasma levels of dp-ucMGP were significantly elevated in patients with CTD-PAH compared to those with CTD alone. This difference may be attributed to the various underlying systemic diseases present in our CTD-PAH patients. As SSc patients often exhibit subtle systemic immunological activity after the early inflammatory phase in comparison to conditions like SLE or rheumatoid arthritis, there is a potential for increased inflammation in the CTD-PAH group compared to our predominantly SSc based CTD patient cohort47–49. sICPs, far from being mere degradation by-products, actively modulate immune responses both locally and systemically. Compared to traditional markers like CRP, they offer a more nuanced view of inflammation. While the proteins responsible for co-stimulation or inhibition between antigen-presenting cells and T-cells function directly on the cell surface, their soluble forms may operate differently. Our findings of elevated sPD1 in IMID-PAH patients, alongside increased sTIM3, sLAG3, and sCD152 in both IPAH and CTD patients, point towards T-cell exhaustion23. This suggests a long-term ongoing inflammatory response within these patient populations. Our studysuggests that immune involvement in PAH extends beyond CTD-PAH alone. Since dp-ucMGP is correlated with sICPs and clinical signs of immune-mediated disease, this could be a valuable biomarker for distinguishing IMID and non-IMID PAH. The association of increased inflammation and dp-ucMGP in PAH patients might be due to a combination of oxidative stress, vitamin K deficiency, endothelial dysfunction or extensive matrix remodeling, all of which are potentially exacerbated by inflammation. Therefore, future studies need to focus on elucidating the causality between inflammation and dp-ucMGP. Further research with a larger cohort and additional immunological markers, such as interleukins, chemokines, and comparison with immune-cell surface checkpoint proteins, is needed to provide a more detailed perspective of immune activation in specific IPAH patient subtypes who might benefit from immunosuppressive treatment. Most notably, high plasma dp-ucMGP levels demonstrated poorer survival outcomes in IPAH patients. Given its correlation with inflammation and the frequently poorer survival observed in patients with CTD-PAH compared to IPAH patients, inflammation may contribute to inferior survival in the high dp-ucMGP group50. Elevated sIL-2R levels, without increased CRP, further supports the presence of a selective T-cell-mediated immune response. Additionally, the substantially lower DLCO levels in these patients, without underlying parenchymal lung disease, suggest extensive vascular remodeling and inflammation as a cause for higher mortality. These findings highlight the urgent need to identify PAH patients with distinct immunological profiles, as they may benefit from targeted immunosuppressive therapy to potentially improve disease outcomes. dp-ucMGP did not exhibit efficacy as a survival marker in CTEPH patients, potentially due to a different underlying pathophysiological mechanism. While the study of dp-ucMGP as a survival marker in CTD-PAH patients did not yield significant results, it is important to note the limited sample size in this group. Limitations of this study include the small number of patients in the CTD-PAH and CTEPH groups, as well as variability in disease duration before presentation, a common challenge in diagnosing PAH. Using CTD patients allowed us to specifically explore the relationship between sICPs and dp-ucMGP levels in an inflammatory disease context that shares similarities with PAH. However, including another control group of patients with non-PAH related cardiovascular disease could provide additional insights into the specificity and relevance of our findings. Future investigations should delve into the clinical role of dp-ucMGP as a biomarker for inflammation and in-vitro experiments in PAH to establish a compelling rationale for incorporating immunosuppressive treatment in these patients. In conclusion, this study highlights the potential significance of dp-ucMGP as a biomarker in PAH, particularly in IPAH, where elevated levels are associated with immune-mediated disease and poorer survival outcomes. The observed correlations with immune-mediated markers and the lack of correlation with calcification levels indicate the need for further research to elucidate the complex molecular mechanisms involved in vascular remodeling underlying these associations. These findings contribute to our understanding of the pathophysiology of PAH and may pave the way for the development of novel diagnostic and therapeutic strategies. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We gratefully thank Lucienne Debrus-Palmans and Nele Bijnens (Laboratory of Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands) and Lisette Unghethum, Petra Lux, and Cecile Maassen for their technical assistance (Laboratory of Biochemistry, Maastricht University, Maastricht, The Netherlands). We also thank Leon Frenken, MD, for his contribution to the collection of clinical data for this cohort. Author contributions RT wrote the concept of this research article which was adapted to the final version by the other authors. RT and DvD performed the statistical analysis and RT prepared the figures. The final version was approved by all authors. All authors contributed to the concept of the research article. Data availability Data of this research article is provided within the manuscript or supplementary information files. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information R. Tobal, Email: rachid.tobal@mumc.nl J. Potjewijd, Email: judith.potjewijd@mumc.nl 5. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement Data of this research article is provided within the manuscript or supplementary information files.